Legal & General Group
NVCT icon

Legal & General Group’s Nuvectis Pharma NVCT Stock Holding History

Legal & General Group’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.06K Sell
1,172
-262
-18% -$2.24K ﹤0.01% 3203
2025
Q4 		$10.8K Hold
1,434
– – ﹤0.01% 3229
2025
Q3 		$8.63K Hold
1,434
– – ﹤0.01% 3318
2025
Q2 		$10.7K Buy
+1,434
New +$13K ﹤0.01% 3270
2024
Q2 		– Sell
-841
Closed -$6.9K – 3478
2024
Q1 		$6.9K Hold
841
– – ﹤0.01% 3258
2023
Q4 		$7.01K Hold
841
– – ﹤0.01% 3282
2023
Q3 		$10.8K Hold
841
– – ﹤0.01% 3251
2023
Q2 		$13.4K Buy
+841
New +$13.4K ﹤0.01% 3262

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Legal & General Group's NVCT Position: Q1 2026 in Review

Legal & General Group reduced its Nuvectis Pharma (NVCT) stake by 18% in Q1 2026, selling an estimated $2.24K and leaving 1,172 shares worth $9.06K. The position accounts for ﹤0.01% of the portfolio, ranked #3203.

Legal & General Group first reported a position in NVCT in Q2 2023 and has held it in 8 quarters since. The position peaked at $13.4K in Q2 2023. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Legal & General Group held 1,172 shares of Nuvectis Pharma worth $9.06K as of Q1 2026.
  • Legal & General Group sold 262 Nuvectis Pharma shares in Q1 2026, an estimated $2.24K.
  • Nuvectis Pharma made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3203 holding.
  • Legal & General Group first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 8 quarters since.
  • Legal & General Group's Nuvectis Pharma position peaked at $13.4K in Q2 2023.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.